Difference between revisions of "CNS5:Volunteer Assignments and Opportunities"
Jump to navigation
Jump to search
[checked revision] | [checked revision] |
(20 intermediate revisions by 2 users not shown) | |||
Line 5: | Line 5: | ||
If empty (no name is present), please volunteer to create content for that disease! | If empty (no name is present), please volunteer to create content for that disease! | ||
− | To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | + | To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br /> |
− | + | __TOC__ | |
− | <br /> | ||
{| class="wikitable" style="margin:auto" | {| class="wikitable" style="margin:auto" | ||
|+<big>WHO Classification of Tumours of the Central Nervous System (5th Edition) Content</big> | |+<big>WHO Classification of Tumours of the Central Nervous System (5th Edition) Content</big> | ||
Line 19: | Line 18: | ||
!'''Notes''' | !'''Notes''' | ||
|- | |- | ||
− | | | + | | |
+ | ====CHAPTER 2 (GLIOMAS, GLIONEURONAL TUMOURS, AND NEURONAL TUMOURS)==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[CNS5:Astrocytoma,_IDH-mutant|Astrocytoma, IDH-mutant]] | ||
|Disease | |Disease | ||
|Meenakshi Mehrotra | |Meenakshi Mehrotra | ||
Line 30: | Line 50: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Oligodendroglioma, IDH- | + | |[[CNS5:Oligodendroglioma,_IDH-mutant_and_1p/19q-codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted]] |
+ | |Disease | ||
+ | |Riley Lochner (trainee), Shashi Shetty (mentor) | ||
|6/7/2022 | |6/7/2022 | ||
| | | | ||
Line 39: | Line 61: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Glioblastoma, IDH- | + | |[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]] |
+ | |Disease | ||
+ | |Meenakshi Mehrotra | ||
| | | | ||
| | | | ||
Line 46: | Line 70: | ||
|LS | |LS | ||
| | | | ||
− | |Moved from " | + | |Moved from "Glioblastoma, IDH-wildtype" to new page; 2021 template added |
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_astrocytoma,_MYB-_or_MYBL1-altered|Diffuse astrocytoma, MYB- or MYBL1-altered]] |
+ | |Disease | ||
+ | |Scott Smith | ||
|6/27/2023 | |6/27/2023 | ||
| | | | ||
− | | | + | |COMPLETE |
| | | | ||
|LS | |LS | ||
Line 57: | Line 83: | ||
|2021 template added (page created 6/27/23) | |2021 template added (page created 6/27/23) | ||
|- | |- | ||
− | |Angiocentric | + | |[[CNS5:Angiocentric_glioma|Angiocentric glioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 66: | Line 94: | ||
| | | | ||
|- | |- | ||
− | |Polymorphous | + | |[[CNS5:Polymorphous_low-grade_neuroepithelial_tumour_of_the_young|Polymorphous low-grade neuroepithelial tumour of the young]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 75: | Line 105: | ||
| | | | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_low-grade_glioma,_MAPK_pathway-altered_|Diffuse low-grade glioma, MAPK pathway-altered]] |
− | + | |Disease | |
− | | | + | |Scott Smith |
− | | | + | |5/3/2024 |
| | | | ||
+ | |PENDING | ||
| | | | ||
+ | |LS | ||
| | | | ||
| | | | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]] |
+ | |Disease | ||
+ | |Laveniya Satgunaseelan (Linda Cooley - previous version) | ||
| | | | ||
| | | | ||
Line 93: | Line 127: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_hemispheric_glioma,_H3_G34-mutant|Diffuse hemispheric glioma, H3 G34-mutant]] |
+ | |Disease | ||
+ | |Xiaolin (Lynn) Hu | ||
|2/21/2022 | |2/21/2022 | ||
| | | | ||
Line 102: | Line 138: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Diffuse | + | !'''Disease''' |
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | |[[CNS5:Diffuse_paediatric-type_high-grade_glioma,_H3-wildtype_and_IDH-wildtype|Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype]] | ||
+ | |Disease | ||
+ | |Madina Sukhanova | ||
|10/28/2022 | |10/28/2022 | ||
| | | | ||
Line 111: | Line 160: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Infant- | + | |[[CNS5:Infant-type_hemispheric_glioma|Infant-type hemispheric glioma]] |
+ | |Disease | ||
| | | | ||
| | | | ||
Line 118: | Line 168: | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
| | | | ||
− | |PENDING | + | | |
+ | |- | ||
+ | |[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]] | ||
+ | |Disease | ||
+ | |Jeremy Pulvers | ||
+ | |9/13/2022<br /> | ||
+ | | | ||
+ | |PENDING | ||
| | | | ||
|LS | |LS | ||
Line 129: | Line 182: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |High- | + | |[[CNS5:High-grade_astrocytoma_with_piloid_features|High-grade astrocytoma with piloid features]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 138: | Line 193: | ||
| | | | ||
|- | |- | ||
− | |Pleomorphic | + | |[[CNS5:Pleomorphic_xanthoastrocytoma|Pleomorphic xanthoastrocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 147: | Line 204: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Subependymal | + | |[[CNS5:Subependymal_giant_cell_astrocytoma|Subependymal giant cell astrocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 156: | Line 215: | ||
| | | | ||
|- | |- | ||
− | |Chordoid | + | |[[CNS5:Chordoid_glioma|Chordoid glioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 165: | Line 226: | ||
| | | | ||
|- | |- | ||
− | |Astroblastoma, MN1- | + | |[[CNS5:Astroblastoma,_MN1-altered|Astroblastoma, MN1-altered]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 174: | Line 237: | ||
| | | | ||
|- | |- | ||
− | |Ganglioglioma||Disease | + | |[[CNS5:Ganglioglioma|Ganglioglioma]] |
+ | |Disease | ||
+ | |Leila Moayed-Aloei | ||
|6/30/2022 | |6/30/2022 | ||
| | | | ||
Line 183: | Line 248: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Gangliocytoma||Disease | + | |[[CNS5:Gangliocytoma|Gangliocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 192: | Line 259: | ||
| | | | ||
|- | |- | ||
− | |Desmoplastic | + | !'''Disease''' |
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | |[[CNS5:Desmoplastic_infantile_ganglioglioma_/_desmoplastic_infantile_astrocytoma|Desmoplastic infantile ganglioglioma / desmoplastic infantile astrocytoma]] | ||
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 201: | Line 281: | ||
| | | | ||
|- | |- | ||
− | |Dysembryoplastic | + | |[[CNS5:Dysembryoplastic_neuroepithelial_tumour|Dysembryoplastic neuroepithelial tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 210: | Line 292: | ||
| | | | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_glioneuronal_tumour_with_oligodendroglioma-like_features_and_nuclear_clusters|Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 219: | Line 303: | ||
| | | | ||
|- | |- | ||
− | |Papillary | + | |[[CNS5:Papillary_glioneuronal_tumour|Papillary glioneuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 228: | Line 314: | ||
| | | | ||
|- | |- | ||
− | |Rosette- | + | |[[CNS5:Rosette-forming_glioneuronal_tumour|Rosette-forming glioneuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 237: | Line 325: | ||
| | | | ||
|- | |- | ||
− | |Myxoid | + | |[[CNS5:Myxoid_glioneuronal_tumour|Myxoid glioneuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 246: | Line 336: | ||
| | | | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_leptomeningeal_glioneuronal_tumour|Diffuse leptomeningeal glioneuronal tumour]] |
+ | |Disease | ||
+ | |Laveniya Satgunaseelan | ||
+ | |9/11/2024 | ||
| | | | ||
+ | |Pending | ||
| | | | ||
| | | | ||
| | | | ||
+ | |Testing 9/2024 somatic template | ||
+ | |- | ||
+ | |[[CNS5:Multinodular_and_vacuolating_neuronal_tumour|Multinodular and vacuolating neuronal tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 261: | Line 357: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:Dysplastic_cerebellar_gangliocytoma_(Lhermitte-Duclos_disease)|Dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease)]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 271: | Line 368: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:Central_neurocytoma|Central neurocytoma]] | ||
+ | |Disease | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 282: | Line 380: | ||
| | | | ||
|- | |- | ||
− | |Extraventricular | + | !'''Disease''' |
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | |[[CNS5:Extraventricular_neurocytoma|Extraventricular neurocytoma]] | ||
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 291: | Line 402: | ||
| | | | ||
|- | |- | ||
− | |Cerebellar | + | |[[CNS5:Cerebellar_liponeurocytoma|Cerebellar liponeurocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 300: | Line 413: | ||
| | | | ||
|- | |- | ||
− | |Supratentorial | + | |[[CNS5:Supratentorial_ependymoma|Supratentorial ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 309: | Line 424: | ||
| | | | ||
|- | |- | ||
− | |Supratentorial | + | |[[CNS5:Supratentorial_ependymoma,_ZFTA_fusion-positive_|Supratentorial ependymoma, ZFTA fusion-positive]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 318: | Line 435: | ||
| | | | ||
|- | |- | ||
− | |Supratentorial | + | |[[CNS5:Supratentorial_ependymoma,_YAP1_fusion-positive|Supratentorial ependymoma, YAP1 fusion-positive]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 327: | Line 446: | ||
| | | | ||
|- | |- | ||
− | |Posterior | + | |[[CNS5:Posterior_fossa_ependymoma|Posterior fossa ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 336: | Line 457: | ||
| | | | ||
|- | |- | ||
− | |Posterior | + | |[[CNS5:Posterior_fossa_group_A_(PFA)_ependymoma|Posterior fossa group A (PFA) ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 345: | Line 468: | ||
| | | | ||
|- | |- | ||
− | |Posterior | + | |[[CNS5:Posterior_fossa_group_B_(PFB)_ependymoma|Posterior fossa group B (PFB) ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 354: | Line 479: | ||
| | | | ||
|- | |- | ||
− | |Spinal | + | |[[CNS5:Spinal_ependymoma|Spinal ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 363: | Line 490: | ||
| | | | ||
|- | |- | ||
− | |Spinal | + | |[[CNS5:Spinal_ependymoma,_MYCN-amplified|Spinal ependymoma, MYCN-amplified]] |
+ | |Disease | ||
| | | | ||
| | | | ||
Line 371: | Line 499: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | |- | ||
+ | !'''Disease''' | ||
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
|- | |- | ||
− | |Myxopapillary | + | |[[CNS5:Myxopapillary_ependymoma|Myxopapillary ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 381: | Line 523: | ||
| | | | ||
|- | |- | ||
− | |Subependymoma||Disease | + | |[[CNS5:Subependymoma|Subependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 390: | Line 534: | ||
| | | | ||
|- | |- | ||
− | |||
| | | | ||
+ | ====CHAPTER 3 (CHOROID PLEXUS TUMOURS)==== | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
− | |||
− | |||
− | |||
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[CNS5:Choroid_plexus_papilloma|Choroid plexus papilloma]] | ||
+ | |Disease | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 417: | Line 566: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Atypical_choroid_plexus_papilloma|Atypical choroid plexus papilloma]] |
− | + | |Disease | |
| | | | ||
− | |||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 433: | Line 576: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:Choroid_plexus_carcinoma|Choroid plexus carcinoma]] | ||
+ | |Disease | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 444: | Line 588: | ||
| | | | ||
|- | |- | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
+ | ====CHAPTER 4 (EMBRYONAL TUMOURS)==== | ||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Medulloblastoma,_WNT-activated|Medulloblastoma, WNT-activated]] |
+ | |Disease | ||
+ | |Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City | ||
+ | |9/20/21 | ||
+ | | | ||
+ | |COMPLETE | ||
+ | | | ||
+ | |Holli Drendel (interim)/Laveniya Satgunaseelan (LS) | ||
+ | |9/22/2022 | ||
+ | |2021 template added | ||
+ | |- | ||
+ | |[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-wildtype|Medulloblastoma, SHH-activated and TP53-wildtype]] | ||
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 471: | Line 631: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 480: | Line 642: | ||
| | | | ||
|- | |- | ||
− | | | + | !'''Disease''' |
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | |[[CNS5:Medulloblastoma,_non-WNT/non-SHH|Medulloblastoma, non-WNT/non-SHH]] | ||
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 489: | Line 664: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Medulloblastoma,_histologically_defined|Medulloblastoma, histologically defined]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 498: | Line 675: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Atypical_teratoid/rhabdoid_tumour|Atypical teratoid/rhabdoid tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 507: | Line 686: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Cribriform_neuroepithelial_tumour|Cribriform neuroepithelial tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 516: | Line 697: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Embryonal_tumour_with_multilayered_rosettes|Embryonal tumour with multilayered rosettes]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 525: | Line 708: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:CNS_neuroblastoma,_FOXR2-activated|CNS neuroblastoma, FOXR2-activated]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 534: | Line 719: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:CNS_tumour_with_BCOR_internal_tandem_duplication|CNS tumour with BCOR internal tandem duplication]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 543: | Line 730: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:CNS_embryonal_tumour_NEC/NOS|CNS embryonal tumour NEC/NOS]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 552: | Line 741: | ||
| | | | ||
|- | |- | ||
− | |||
| | | | ||
+ | ====CHAPTER 5 (PINEAL TUMOURS)==== | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[CNS5:Pineocytoma|Pineocytoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | !'''Disease''' | ||
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | |[[CNS5:Pineal_parenchymal_tumour_of_intermediate_differentiation|Pineal parenchymal tumour of intermediate differentiation]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 586: | Line 794: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:Pineoblastoma|Pineoblastoma]] | ||
+ | |Disease | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 597: | Line 806: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Papillary_tumour_of_the_pineal_region|Papillary tumour of the pineal region]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 606: | Line 817: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Desmoplastic_myxoid_tumour_of_the_pineal_region,_SMARCB1-mutant|Desmoplastic myxoid tumour of the pineal region, SMARCB1-mutant]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 615: | Line 828: | ||
| | | | ||
|- | |- | ||
− | |||
| | | | ||
+ | ====CHAPTER 6 (CRANIAL AND PARASPINAL NERVE TUMOURS)==== | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[CNS5:Schwannoma|Schwannoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:Neurofibroma|Neurofibroma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 648: | Line 870: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:Perineurioma|Perineurioma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 658: | Line 881: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:Hybrid_nerve_sheath_tumours|Hybrid nerve sheath tumours]] | ||
+ | |Disease | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 669: | Line 893: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Malignant_melanotic_nerve_sheath_tumour|Malignant melanotic nerve sheath tumour]] |
+ | |Disease | ||
| | | | ||
| | | | ||
Line 677: | Line 902: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | |- | ||
+ | !'''Disease''' | ||
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
|- | |- | ||
− | | | + | |[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 687: | Line 926: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Cauda_equina_neuroendocrine_tumour_(previously_paraganglioma)|Cauda equina neuroendocrine tumour (previously paraganglioma)]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 696: | Line 937: | ||
| | | | ||
|- | |- | ||
− | |||
| | | | ||
+ | ====CHAPTER 7 (MENINGIOMA)==== | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[CNS5:Meningioma|Meningioma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
| | | | ||
+ | ====CHAPTER 8 (MESENCHYMAL, NON-MENINGOTHELIAL TUMOURS INVOLVING THE CNS)==== | ||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Solitary_fibrous_tumour|Solitary fibrous tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 741: | Line 1,001: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Haemangiomas_and_vascular_malformations|Haemangiomas and vascular malformations]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 750: | Line 1,012: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Haemangioblastoma|Haemangioblastoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 759: | Line 1,023: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Rhabdomyosarcoma|Rhabdomyosarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 768: | Line 1,034: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Intracranial_mesenchymal_tumour,_FET::CREB_fusion-positive|Intracranial mesenchymal tumour, FET::CREB fusion-positive]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 777: | Line 1,045: | ||
| | | | ||
|- | |- | ||
− | | | + | !'''Disease''' |
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | |[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]] | ||
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 786: | Line 1,067: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Primary_intracranial_sarcoma,_DICER1-mutant|Primary intracranial sarcoma, DICER1-mutant]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 795: | Line 1,078: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Ewing_sarcoma|Ewing sarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 804: | Line 1,089: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Mesenchymal_chondrosarcoma|Mesenchymal chondrosarcoma]] |
− | + | |Disease | |
| | | | ||
− | |||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 820: | Line 1,099: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:Chondrosarcoma|Chondrosarcoma]] | ||
+ | |Disease | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 831: | Line 1,111: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Chordoma|Chordoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 840: | Line 1,122: | ||
| | | | ||
|- | |- | ||
− | |||
| | | | ||
+ | ====CHAPTER 9 (MELANOCYTIC TUMOURS)==== | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[CNS5:Diffuse_meningeal_melanocytic_neoplasms:_Melanocytosis_and_melanomatosis|Diffuse meningeal melanocytic neoplasms: Melanocytosis and melanomatosis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:Circumscribed_meningeal_melanocytic_neoplasms:_Melanocytoma_and_melanoma|Circumscribed meningeal melanocytic neoplasms: Melanocytoma and melanoma]] | ||
+ | |Disease | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 876: | Line 1,165: | ||
| | | | ||
|- | |- | ||
− | |||
| | | | ||
+ | ====CHAPTER 10 (HAEMATOLYMPHOID TUMOURS INVOLVING THE CNS)==== | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
− | |||
− | |||
− | |||
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[CNS5:Primary_diffuse_large_B-cell_lymphoma_of_the_CNS|Primary diffuse large B-cell lymphoma of the CNS]] | ||
+ | |Disease | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 903: | Line 1,197: | ||
| | | | ||
|- | |- | ||
− | + | !'''Disease''' | |
− | | | + | !'''Page Type''' |
− | | | + | !'''<span style="color:#0070C0">Author''' |
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | |[[CNS5:Immunodeficiency-associated_CNS_lymphomas|Immunodeficiency-associated CNS lymphomas]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 911: | Line 1,215: | ||
| | | | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:Lymphomatoid_granulomatosis|Lymphomatoid granulomatosis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:Intravascular_large_B-cell_lymphoma|Intravascular large B-cell lymphoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 936: | Line 1,240: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[CNS5:MALT_lymphoma_of_the_dura|MALT lymphoma of the dura]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 946: | Line 1,251: | ||
| | | | ||
| | | | ||
− | |||
|- | |- | ||
− | | | + | |[[CNS5:Other_low-grade_B-cell_lymphomas_of_the_CNS|Other low-grade B-cell lymphomas of the CNS]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 957: | Line 1,263: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Anaplastic_large_cell_lymphoma_(ALK+/ALK−)|Anaplastic large cell lymphoma (ALK+/ALK−)]] |
+ | |Disease | ||
+ | |Jennie Thurston | ||
+ | |7/2/2023 | ||
+ | | | ||
+ | |PENDING | ||
+ | | | ||
+ | |MS | ||
+ | | | ||
+ | |2021 template added; Did not yet convert to CNS5 namespace. Should Jennie instead do the related two pages in HAEM5 of "[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]" and "[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]"? | ||
+ | |- | ||
+ | |[[CNS5:T-cell_and_NK/T-cell_lymphomas|T-cell and NK/T-cell lymphomas]] | ||
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 966: | Line 1,285: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Erdheim-Chester_disease|Erdheim-Chester disease]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 975: | Line 1,296: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Rosai-Dorfman_disease|Rosai-Dorfman disease]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 984: | Line 1,307: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Juvenile_xanthogranuloma|Juvenile xanthogranuloma]] |
+ | |Disease | ||
| | | | ||
| | | | ||
Line 992: | Line 1,316: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | |- | ||
+ | !'''Disease''' | ||
+ | !'''Page Type''' | ||
+ | !'''<span style="color:#0070C0">Author''' | ||
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
|- | |- | ||
− | | | + | |[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,002: | Line 1,340: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Histiocytic_sarcoma|Histiocytic sarcoma]] |
− | + | |Disease | |
| | | | ||
− | |||
| | | | ||
− | |||
| | | | ||
− | |||
− | |||
− | |||
− | |||
| | | | ||
− | |||
| | | | ||
− | |||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
+ | |- | ||
| | | | ||
+ | ====CHAPTER 11 (GERM CELL TUMOURS)==== | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
− | |||
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[CNS5:Germ_cell_tumours_of_the_CNS|Germ cell tumours of the CNS]] | ||
+ | |Disease | ||
| | | | ||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,047: | Line 1,383: | ||
| | | | ||
|- | |- | ||
− | |||
− | |||
| | | | ||
− | + | ====CHAPTER 12 (TUMOURS OF THE SELLAR REGION==== | |
| | | | ||
− | + | ---- | |
| | | | ||
− | + | ---- | |
− | |||
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Adamantinomatous_craniopharyngioma|Adamantinomatous craniopharyngioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,074: | Line 1,415: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Papillary_craniopharyngioma|Papillary craniopharyngioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,083: | Line 1,426: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pituicytoma,_granular_cell_tumour_of_the_sellar_region,_and_spindle_cell_oncocytoma|Pituicytoma, granular cell tumour of the sellar region, and spindle cell oncocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,092: | Line 1,437: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pituitary_adenoma_/_pituitary_neuroendocrine_tumour|Pituitary adenoma / pituitary neuroendocrine tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,101: | Line 1,448: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pituitary_blastoma|Pituitary blastoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,110: | Line 1,459: | ||
| | | | ||
|- | |- | ||
− | + | !'''Disease''' | |
− | + | !'''Page Type''' | |
− | + | !'''<span style="color:#0070C0">Author''' | |
− | |||
− | !'''Disease''' | ||
!'''Date Assigned to Author''' | !'''Date Assigned to Author''' | ||
!'''Target Completion Date''' | !'''Target Completion Date''' | ||
!'''Author Content (Pending or Complete)''' | !'''Author Content (Pending or Complete)''' | ||
− | !'''Date Completed by Author''' | + | !'''Date Completed by Author''' |
+ | !'''Associate Editor''' | ||
!'''Date of Last Editor Review''' | !'''Date of Last Editor Review''' | ||
!'''Notes''' | !'''Notes''' | ||
|- | |- | ||
− | |||
− | |||
− | |||
− | |||
| | | | ||
− | + | ====CHAPTER 13 (METASTASES TO THE CNS)==== | |
| | | | ||
− | + | ---- | |
| | | | ||
− | + | ---- | |
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
− | + | ---- | |
| | | | ||
− | + | ---- | |
| | | | ||
− | + | ---- | |
− | |||
− | |||
− | |||
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
| | | | ||
− | + | ---- | |
| | | | ||
− | + | ---- | |
|- | |- | ||
− | |[[CNS5: | + | |[[CNS5:Metastases_to_the_brain_and_spinal_cord_parenchyma|Metastases to the brain and spinal cord parenchyma]] |
|Disease | |Disease | ||
− | |||
− | |||
| | | | ||
− | |||
| | | | ||
− | |||
| | | | ||
− | | | + | | |
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
|- | |- | ||
− | |[[CNS5: | + | |[[CNS5:Metastases_to_the_meninges|Metastases to the meninges]] |
|Disease | |Disease | ||
| | | | ||
Line 1,177: | Line 1,513: | ||
| | | | ||
|- | |- | ||
− | |||
− | |||
| | | | ||
+ | ====CHAPTER 14 (GENETIC TUMOUR SYNDROMES INVOLVING THE CNS)==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[CNS5:Neurofibromatosis_type_1|Neurofibromatosis type 1]] | ||
+ | |Disease | ||
+ | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |- | ||
+ | |[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]] | ||
+ | |Disease | ||
+ | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
|- | |- | ||
− | |[[CNS5: | + | |[[CNS5:Schwannomatosis|Schwannomatosis]] |
|Disease | |Disease | ||
| | | | ||
Line 1,199: | Line 1,567: | ||
| | | | ||
|- | |- | ||
− | |[[CNS5: | + | |[[CNS5:Von_Hippel-Lindau_syndrome|Von Hippel-Lindau syndrome]] |
|Disease | |Disease | ||
− | | | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |- | ||
+ | |[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]] | ||
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
− | |||
| | | | ||
− | |||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
− | |||
| | | | ||
− | |||
| | | | ||
− | |||
|- | |- | ||
− | |[[CNS5: | + | |[[CNS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]] |
|Disease | |Disease | ||
− | | | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
− | |[[CNS5: | + | !'''Disease''' |
− | |Disease | + | !'''Page Type''' |
− | | | + | !'''<span style="color:#0070C0">Author''' |
+ | !'''Date Assigned to Author''' | ||
+ | !'''Target Completion Date''' | ||
+ | !'''Author Content (Pending or Complete)''' | ||
+ | !'''Date Completed by Author''' | ||
+ | !'''Associate Editor''' | ||
+ | !'''Date of Last Editor Review''' | ||
+ | !'''Notes''' | ||
+ | |- | ||
+ | |[[CNS5:Cowden_syndrome|Cowden syndrome]] | ||
+ | |Disease | ||
+ | |[[DIG5:Volunteer Assignments and Opportunities|See DIG5 volunteer sheet for authorship status]] | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |- | ||
+ | |[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]] | ||
+ | |Disease | ||
+ | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |- | ||
+ | |[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]] | ||
+ | |Disease | ||
+ | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |- | ||
+ | |[[CNS5:Naevoid_basal_cell_carcinoma_syndrome|Naevoid basal cell carcinoma syndrome]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,241: | Line 1,652: | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
− | |||
| | | | ||
− | |||
|- | |- | ||
− | |[[CNS5: | + | |[[CNS5:Rhabdoid_tumour_predisposition_syndrome|Rhabdoid tumour predisposition syndrome]] |
|Disease | |Disease | ||
| | | | ||
Line 1,265: | Line 1,666: | ||
| | | | ||
|- | |- | ||
− | |[[CNS5: | + | |[[CNS5:Carney_complex|Carney complex]] |
|Disease | |Disease | ||
| | | | ||
Line 1,276: | Line 1,677: | ||
| | | | ||
|- | |- | ||
− | |[[CNS5: | + | |[[CNS5:DICER1_syndrome|DICER1 syndrome]] |
|Disease | |Disease | ||
− | | | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
− | |[[CNS5: | + | |[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]] |
|Disease | |Disease | ||
| | | | ||
Line 1,298: | Line 1,699: | ||
| | | | ||
|- | |- | ||
− | |[[CNS5: | + | |[[CNS5:Melanoma-astrocytoma_syndrome|Melanoma-astrocytoma syndrome]] |
|Disease | |Disease | ||
| | | | ||
Line 1,309: | Line 1,710: | ||
| | | | ||
|- | |- | ||
− | |[[CNS5: | + | |[[CNS5:Familial_retinoblastoma|Familial retinoblastoma]] |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
|Disease | |Disease | ||
| | | | ||
Line 1,331: | Line 1,721: | ||
| | | | ||
|- | |- | ||
− | + | !'''Disease''' | |
− | + | !'''Page Type''' | |
− | + | !'''<span style="color:#0070C0">Author''' | |
− | + | !'''Date Assigned to Author''' | |
− | + | !'''Target Completion Date''' | |
− | + | !'''Author Content (Pending or Complete)''' | |
− | + | !'''Date Completed by Author''' | |
− | + | !'''Associate Editor''' | |
− | + | !'''Date of Last Editor Review''' | |
− | + | !'''Notes''' | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
|[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]] | |[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]] | ||
Line 2,433: | Line 1,745: | ||
|[[CNS5:Fanconi_anaemia|Fanconi anaemia]] | |[[CNS5:Fanconi_anaemia|Fanconi anaemia]] | ||
|Disease | |Disease | ||
− | | | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
|[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]] | |[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]] |
Latest revision as of 08:53, 11 September 2024
Welcome!
For assignments, please see the "Author" column below (highlighted blue).
If empty (no name is present), please volunteer to create content for that disease!
To volunteer, please [Contact us] with your page of interest.
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
---|---|---|---|---|---|---|---|---|---|
CHAPTER 2 (GLIOMAS, GLIONEURONAL TUMOURS, AND NEURONAL TUMOURS) |
|
|
|
|
|
|
|
|
|
Astrocytoma, IDH-mutant | Disease | Meenakshi Mehrotra | 6/25/2023 | PENDING | Laveniya Satgunaseelan (LS) | 2021 template added | |||
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted | Disease | Riley Lochner (trainee), Shashi Shetty (mentor) | 6/7/2022 | COMPLETE | LS | 2021 template added | |||
Glioblastoma, IDH-wildtype | Disease | Meenakshi Mehrotra | PENDING | LS | Moved from "Glioblastoma, IDH-wildtype" to new page; 2021 template added | ||||
Diffuse astrocytoma, MYB- or MYBL1-altered | Disease | Scott Smith | 6/27/2023 | COMPLETE | LS | 2021 template added (page created 6/27/23) | |||
Angiocentric glioma | Disease | ||||||||
Polymorphous low-grade neuroepithelial tumour of the young | Disease | ||||||||
Diffuse low-grade glioma, MAPK pathway-altered | Disease | Scott Smith | 5/3/2024 | PENDING | LS | ||||
Diffuse midline glioma, H3 K27-altered | Disease | Laveniya Satgunaseelan (Linda Cooley - previous version) | PENDING | LS | 2021 template added | ||||
Diffuse hemispheric glioma, H3 G34-mutant | Disease | Xiaolin (Lynn) Hu | 2/21/2022 | COMPLETE | LS | 2021 template added | |||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype | Disease | Madina Sukhanova | 10/28/2022 | COMPLETE | LS | 2021 template added | |||
Infant-type hemispheric glioma | Disease | ||||||||
Pilocytic astrocytoma | Disease | Jeremy Pulvers | 9/13/2022 |
PENDING | LS | 2021 template added | |||
High-grade astrocytoma with piloid features | Disease | ||||||||
Pleomorphic xanthoastrocytoma | Disease | LS | 2021 template added | ||||||
Subependymal giant cell astrocytoma | Disease | ||||||||
Chordoid glioma | Disease | ||||||||
Astroblastoma, MN1-altered | Disease | ||||||||
Ganglioglioma | Disease | Leila Moayed-Aloei | 6/30/2022 | COMPLETE | LS | 2021 template added | |||
Gangliocytoma | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Desmoplastic infantile ganglioglioma / desmoplastic infantile astrocytoma | Disease | ||||||||
Dysembryoplastic neuroepithelial tumour | Disease | ||||||||
Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters | Disease | ||||||||
Papillary glioneuronal tumour | Disease | ||||||||
Rosette-forming glioneuronal tumour | Disease | ||||||||
Myxoid glioneuronal tumour | Disease | ||||||||
Diffuse leptomeningeal glioneuronal tumour | Disease | Laveniya Satgunaseelan | 9/11/2024 | Pending | Testing 9/2024 somatic template | ||||
Multinodular and vacuolating neuronal tumour | Disease | ||||||||
Dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease) | Disease | ||||||||
Central neurocytoma | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Extraventricular neurocytoma | Disease | ||||||||
Cerebellar liponeurocytoma | Disease | ||||||||
Supratentorial ependymoma | Disease | ||||||||
Supratentorial ependymoma, ZFTA fusion-positive | Disease | ||||||||
Supratentorial ependymoma, YAP1 fusion-positive | Disease | ||||||||
Posterior fossa ependymoma | Disease | ||||||||
Posterior fossa group A (PFA) ependymoma | Disease | ||||||||
Posterior fossa group B (PFB) ependymoma | Disease | ||||||||
Spinal ependymoma | Disease | ||||||||
Spinal ependymoma, MYCN-amplified | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Myxopapillary ependymoma | Disease | ||||||||
Subependymoma | Disease | ||||||||
CHAPTER 3 (CHOROID PLEXUS TUMOURS) |
|
|
|
|
|
|
|
|
|
Choroid plexus papilloma | Disease | ||||||||
Atypical choroid plexus papilloma | Disease | ||||||||
Choroid plexus carcinoma | Disease | ||||||||
CHAPTER 4 (EMBRYONAL TUMOURS) |
|
|
|
|
|
|
|
|
|
Medulloblastoma, WNT-activated | Disease | Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City | 9/20/21 | COMPLETE | Holli Drendel (interim)/Laveniya Satgunaseelan (LS) | 9/22/2022 | 2021 template added | ||
Medulloblastoma, SHH-activated and TP53-wildtype | Disease | ||||||||
Medulloblastoma, SHH-activated and TP53-mutant | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Medulloblastoma, non-WNT/non-SHH | Disease | ||||||||
Medulloblastoma, histologically defined | Disease | ||||||||
Atypical teratoid/rhabdoid tumour | Disease | ||||||||
Cribriform neuroepithelial tumour | Disease | ||||||||
Embryonal tumour with multilayered rosettes | Disease | ||||||||
CNS neuroblastoma, FOXR2-activated | Disease | ||||||||
CNS tumour with BCOR internal tandem duplication | Disease | ||||||||
CNS embryonal tumour NEC/NOS | Disease | ||||||||
CHAPTER 5 (PINEAL TUMOURS) |
|
|
|
|
|
|
|
|
|
Pineocytoma | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Pineal parenchymal tumour of intermediate differentiation | Disease | ||||||||
Pineoblastoma | Disease | ||||||||
Papillary tumour of the pineal region | Disease | ||||||||
Desmoplastic myxoid tumour of the pineal region, SMARCB1-mutant | Disease | ||||||||
CHAPTER 6 (CRANIAL AND PARASPINAL NERVE TUMOURS) |
|
|
|
|
|
|
|
|
|
Schwannoma | Disease | ||||||||
Neurofibroma | Disease | ||||||||
Perineurioma | Disease | ||||||||
Hybrid nerve sheath tumours | Disease | ||||||||
Malignant melanotic nerve sheath tumour | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Malignant peripheral nerve sheath tumour | Disease | ||||||||
Cauda equina neuroendocrine tumour (previously paraganglioma) | Disease | ||||||||
CHAPTER 7 (MENINGIOMA) |
|
|
|
|
|
|
|
|
|
Meningioma | Disease | ||||||||
CHAPTER 8 (MESENCHYMAL, NON-MENINGOTHELIAL TUMOURS INVOLVING THE CNS) |
|
|
|
|
|
|
|
|
|
Solitary fibrous tumour | Disease | ||||||||
Haemangiomas and vascular malformations | Disease | ||||||||
Haemangioblastoma | Disease | ||||||||
Rhabdomyosarcoma | Disease | ||||||||
Intracranial mesenchymal tumour, FET::CREB fusion-positive | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
CIC-rearranged sarcoma | Disease | ||||||||
Primary intracranial sarcoma, DICER1-mutant | Disease | ||||||||
Ewing sarcoma | Disease | ||||||||
Mesenchymal chondrosarcoma | Disease | ||||||||
Chondrosarcoma | Disease | ||||||||
Chordoma | Disease | ||||||||
CHAPTER 9 (MELANOCYTIC TUMOURS) |
|
|
|
|
|
|
|
|
|
Diffuse meningeal melanocytic neoplasms: Melanocytosis and melanomatosis | Disease | ||||||||
Circumscribed meningeal melanocytic neoplasms: Melanocytoma and melanoma | Disease | ||||||||
CHAPTER 10 (HAEMATOLYMPHOID TUMOURS INVOLVING THE CNS) |
|
|
|
|
|
|
|
|
|
Primary diffuse large B-cell lymphoma of the CNS | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Immunodeficiency-associated CNS lymphomas | Disease | ||||||||
Lymphomatoid granulomatosis | Disease | ||||||||
Intravascular large B-cell lymphoma | Disease | ||||||||
MALT lymphoma of the dura | Disease | ||||||||
Other low-grade B-cell lymphomas of the CNS | Disease | ||||||||
Anaplastic large cell lymphoma (ALK+/ALK−) | Disease | Jennie Thurston | 7/2/2023 | PENDING | MS | 2021 template added; Did not yet convert to CNS5 namespace. Should Jennie instead do the related two pages in HAEM5 of "ALK-positive anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)" and "ALK-negative anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)"? | |||
T-cell and NK/T-cell lymphomas | Disease | ||||||||
Erdheim-Chester disease | Disease | ||||||||
Rosai-Dorfman disease | Disease | ||||||||
Juvenile xanthogranuloma | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Langerhans cell histiocytosis | Disease | ||||||||
Histiocytic sarcoma | Disease | ||||||||
CHAPTER 11 (GERM CELL TUMOURS) |
|
|
|
|
|
|
|
|
|
Germ cell tumours of the CNS | Disease | ||||||||
CHAPTER 12 (TUMOURS OF THE SELLAR REGION |
|
|
|
|
|
|
|
|
|
Adamantinomatous craniopharyngioma | Disease | ||||||||
Papillary craniopharyngioma | Disease | ||||||||
Pituicytoma, granular cell tumour of the sellar region, and spindle cell oncocytoma | Disease | ||||||||
Pituitary adenoma / pituitary neuroendocrine tumour | Disease | ||||||||
Pituitary blastoma | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
CHAPTER 13 (METASTASES TO THE CNS) |
|
|
|
|
|
|
|
|
|
Metastases to the brain and spinal cord parenchyma | Disease | ||||||||
Metastases to the meninges | Disease | ||||||||
CHAPTER 14 (GENETIC TUMOUR SYNDROMES INVOLVING THE CNS) |
|
|
|
|
|
|
|
|
|
Neurofibromatosis type 1 | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Neurofibromatosis type 2 | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Schwannomatosis | Disease | ||||||||
Von Hippel-Lindau syndrome | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Tuberous sclerosis | Disease | ||||||||
Li-Fraumeni syndrome | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
Cowden syndrome | Disease | See DIG5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Constitutional mismatch repair deficiency syndrome | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Familial adenomatous polyposis 1 | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Naevoid basal cell carcinoma syndrome | Disease | ||||||||
Rhabdoid tumour predisposition syndrome | Disease | ||||||||
Carney complex | Disease | ||||||||
DICER1 syndrome | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Familial paraganglioma syndromes | Disease | ||||||||
Melanoma-astrocytoma syndrome | Disease | ||||||||
Familial retinoblastoma | Disease | ||||||||
Disease | Page Type | Author | Date Assigned to Author | Target Completion Date | Author Content (Pending or Complete) | Date Completed by Author | Associate Editor | Date of Last Editor Review | Notes |
BAP1 tumour predisposition syndrome | Disease | ||||||||
Fanconi anaemia | Disease | See GTS5 volunteer sheet for authorship status | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ELP1-medulloblastoma syndrome | Disease |